

8.3 Publikationer

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.Sandmaier BM, Kornblit B, Storer BE, Dleszen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. *Lancet Haematol.* 2019 Aug;6(8):e409-e418.

Addressing the room for improvement in management of acute promyelocytic leukemia.Nørgaard JM, Friis LS, Kristensen JS, Severinsen MT, Mølle I, Marcher CW, Møller P, Schoellkopf C, Nielsen DJ, Preiss BS, Andersen MK, Kjeldsen E, Medeiros BC, Østgård LSG; Danish Acute Leukemia Group. *Eur J Haematol.* 2019 Jun;102(6):479-485.

Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia.Løhmann DJA, Asdahl PH, Abrahamsson J, Ha SY, Jónsson ÓG, Kaspers GJL, Koskenvuo M, Lausen B, De Moerloose B, Palle J, Zeller B, Sung L, Hasle H. *Cancer Med.* 2019 Nov;8(15):6634-6643.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.Horwitz S, O'Connor DA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. *Lancet.* 2019 Jan 19;393(10168):229-240.

Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.Vonasek J, Edslev PW, d'Amore F, Hasle H. *Pediatr Blood Cancer.* 2020 Feb;67(2):e28082.

Clinical and neuroimaging features of the m.10197G>A mtDNA mutation: New case reports and expansion of the phenotype variability.Tolomeo D, Rubegni A, Severino M, Pochiero F, Bruno C, Cassandrini D, Madeo A, Doccini S, Pedemonte M, Rossi A, D'Amore F, Donati MA, Di Rocco M, Santorelli FM, Nesti C. *J Neurol Sci.* 2019 Apr 15;399:69-75.

Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.Roug AS, Omnen HB. *Curr Treat Options Oncol.* 2019 Mar 14;20(4):28. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. Bicler JL, El-Galaly TC, Bøgsted M, Jørgensen J, et al. *Leuk Lymphoma.* 2019 Jun;60(6):1580-1583.

Complex multisystem phenotype associated with the mitochondrial DNA m.5522G>A mutation.Nesti C, Rubegni A, Tolomeo D, Baldacci J, Cassandrini D, D'Amore F, Santorelli FM. *Neurol Sci.* 2019 Aug;40(8):1705-1708.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.Facon T, Kumar S, Plesner T, Orłowski RZ, Moreau P, Bahls N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Verner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampaerbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. *N Engl J Med.* 2019 May 30;380(22):2104-2115.

Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma – a nationwide population-based cohort study.Clausen MR, Ulrichsen SP, Larsen TS, Poulsen CB, Tojaga S, Pedersen PT, Madsen J, Pedersen RS, Josefsson PL, Gørløv JS, Nørgaard M, d'Amore F. *Leuk Lymphoma.* 2019 Aug;60(8):1950-1957.

Development in well-being and social function among Danish hemophilia patients with HIV: a three-wave panel study spanning 24 years.Ingvorsen EB, Schnohr C, Andersen T, Lehmann L, Funding E, Poulsen LH, Holm KB, Laursen AL, Gerstoft J, Bjørner JB. *BMC Public Health.* 2019 Dec 19;19(1):1714.

Disease-specific Hospitalizations Among 5-Year Survivors of Hepatoblastoma: A Nordic Population-based Cohort Study.Bonnesen TG, Asdahl PH, de Fine Licht S, Gudmundsdottir T, Holmqvist AS, Madanat-Harjuoja LM, Tryggvadottir L, Winther JF, Hasle AH; ALiCCS Study Group. *J Pediatr Hematol Oncol.* 2019 Apr;41(3):181-186.

Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark.Glimelius I, Englund A, Rostgaard K, Smedby KE, Eloranta S, de Nully Brown P, Johansen C, Kamper P, Ljungman G, Hjalgrim LL, Hjalgrim H. *Cancer Med.* 2019 Aug;8(10):4918-4927.

Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial.Bro ML, Johansen C, Vuust P, Enggaard L, Himmelstrup B, Mourits-Andersen T, Brown P, d'Amore F, Andersen EAW, Abildgaard N, Gram J. *Support Care Cancer.* 2019 Oct;27(10):3887-3896.

Fixed doses of N6-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Toretto A, Wheeler A, Santagostino E. *Res Pract Thromb Haemost.* 2019 Jun 11;3(3):542-554.

Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy.Pedersen MA, Gormsen LC, Kamper P, Wassberg C, Andersen MD, d'Amore AL, Barrington SF, Johnson P, Hamilton-Dutoit S, Amini RM, Enblad G, Molin D, d'Amore F. *Br J Haematol.* 2019 Aug;186(3):431-439.



Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Brazier RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J. *Blood*. 2019 Apr 11;133(15):1664-1676.

High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma. Madsen C, Lauridsen KL, Plesner TL, Monrad I, Honoré B, Hamilton-Dutoit S, d'Amore F, Ludvigsen M. *Blood Cancer J*. 2019 Mar 18;9(4):35.

High intratumoral Galectin-1 expression predicts adverse outcome in ALK-ALCL and CD30+ PTCL. Holst J.M., Ludvigsen M., Hamilton-Dutoit S., Bendix B., Plesner T., Nørgaard P., Møller M.B., Steiniche T., Rabinovich G.A., d'Amore F., Pedersen M.B. *Hematological Oncology*, 2019

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Elees RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broly A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS. *Nat Commun*. 2019 Jan 10;10(1):213.

Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Calabretta E, d'Amore F, Carlo-Stella C. *Int J Mol Sci*. 2019 Nov 5;20(21).

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. *Oncoimmunology*. 2019 Jul 13;8(9):e1638210.

Integrating detection of copy neutral chromosomal losses in a clinical setting in leukemia and lymphoma by means of allelic imbalance and read depth ratio comparison. Hansen M.C., Cédile O., Ludvigsen M., Kjeldsen E., Moeller P.L., Abildgaard N., Hokland P., Nyvold C.G. Preprint BioRxiv. 2019

International external quality assurance of JAK2 V617F quantification. Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N. *Ann Hematol*. 2019 May;98(5):1111-1118.

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with

testicular diffuse large B-cell lymphoma. Mannisto S, Vähämurto P, Pollari M, Clausen MR, Jyrkkö S, Kellokumpu-Lehtinen PL, Kovanen P, Karjalainen-Lindsberg ML, d'Amore F, Leppä S. *Eur J Cancer*. 2019 Jul;115:27-36.

Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. Tøstesen M, Nørgaard M, Nørgaard JM, Medeiros BC, Marcher CW, Overgaard UM, Severinsen MT, Schoellkopf C, Østgård LSG. *Clin Epidemiol*. 2019 Aug 28;11:769-780.

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, Hansen MC, Hamilton-Dutoit SJ, Nørgaard P, Johansen P, Eberlein TR, Mortensen BK, Mathiasen G, Øvlisen A, Wang R, Wang C, Zhang W, Ommen HB, Stentoft J, Ludvigsen M, Tam W, Chan WC, Inghirami G, d'Amore F. *Haematologica*. 2019 Nov 28. pii: haematol.2019.225839.

No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. Jakobsen LH, Biccler JL, Brown PN, Jørgensen JM, Josefsson PL, Poulsen CB, Starklint J, Clausen MR, Pedersen PT, Juul MB, Severinsen MT, Bøgsted M, El-Galaly TC. *Leuk Lymphoma*. 2019 Nov;60(11):2798-2801.

Once-versus twice-daily aspirin treatment in patients with essential thrombocytosis. Larsen ML, Pedersen DH, Hvas AM, Niekerk PBVK, Bønløkke S, Kristensen SD, Grove EL. *Platelets*. 2019;30(3):322-328.

Patients' experiences and perspectives of challenges and needs related to nonmyeloablative stem cell transplantation: Involving patients in developing a targeted rehabilitation programme. Lindman A, Krintel Petersen A, Olesen G, Handberg C. *J Clin Nurs*. 2019 Apr;28(7-8):1260-1272.

Perturbations of urea cycle enzymes during posthepatectomy rat liver failure. Meier M, Knudsen AR, Andersen KJ, Ludvigsen M, Eriksen PL, Pedersen AKN, Honoré B, Mortensen FV. *Am J Physiol Gastrointest Liver Physiol*. 2019 Oct 1;317(4):G429-G440.

Pixantrone beyond monotherapy: a review. Barrenetxea Lekue C, Grasso Cicala S, Leppä S, Stauffer Larsen T, Herráez Rodríguez S, Alonso Caballero C, Jørgensen JM, Tolbod H, Leal Martínez I, D'Amore F. *Ann Hematol*. 2019 Sep;98(9):2025-2033.

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, Himmelstrup B, Rønnow-Jessen D, Link BK, Feldman AL, Slager SL, Nowakowski GS, Thompson CA, Pedersen PT, Madsen J, Pedersen RS, Gørløv JS, Cerhan JR, Nørgaard M, d'Amore F. *Clin Epidemiol*. 2019 Nov 14;11:987-996.

Randomized Phase III Study of AIsertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlag N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattonne CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrisnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. *J Clin Oncol*. 2019 Mar 10;37(8):613-623.

Reproducing the molecular subclassification of peripheral T-cell lymphoma-NDS by immunohistochemistry. Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J. *Blood*. 2019 Dec 12;134(24):2159-2170.

Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L. *Br J Haematol*. 2019 Mar;184(5):769-781.

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Bicclet JL, Savage KJ, Brown PDN, Jørgensen J, Larsen TS, et al. *Leuk Lymphoma*. 2019 Apr 3:1-8

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECTVIII clinical trial. Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG. *Thromb Res*. 2019 Nov;183:13-19.

Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma. Nielsen PI, Hansen SV, Møller MB, Kristensen TK, Cédile D, Hansen MC, Ebbesen LH, Haaber J, Abildgaard N, Nyvold CG. *Leuk Res*. 2019 Mar;78:1-2.

STAT3 Inhibition Specifically in Human Monocytes and Macrophages by CD163-targeted Corosolic Acid-Containing Liposomes. Morten Nørgaard Andersen, Anders Etzerodt, Jonas H Graversen, Lisa C Holthof, Søren K Moestrup, Marianne Hokland, Holger J Møller. *Cancer Immunol Immunother* 2019 Mar;68(3):489-502.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Shapiro AD, Anchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J. *Blood*. 2019 Nov 28;134(22):1973-1982.

The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor \uparrow . Andersen MD, Kamper P, d'Amore A, Clausen M, Bentzen H, d'Amore F. *Leuk Lymphoma*. 2019 Apr;60(4):927-933.

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Frølund UC, Gimsing P, Helleberg C, Vangsted AJ. *Leukemia*. 2019 Feb;33(2):546-549. No abstract available.

Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series. Vianello F, D'Amore F, Lombardi AM, Caputo I, Friziero A, Da Dalt G. *Blood Coagul Fibrinolysis*. 2019 Sep;30(6):295-299.

Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. Løhmann DJA, Asdahl PH, Abrahamsson J, Ha SY, Jónsson ÓG, Kaspers GJL, Koskenvuo M, Lausen B, De Moerloose B, Palle J, Zeller B, Hasle H. *Pediatr Blood Cancer*. 2019 Jun;66(6):e27701.

Value of detecting bone marrow involvement in Hodgkin lymphoma – Response to Adams and Kwee. Pedersen MA, Gormsen LC, d'Amore F. *Br J Haematol*. 2019 Nov;187(3):396-397.

Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Kjaer L, Skov V, Andersen MT, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MH, Hasselbalch H, Pallisgaard N. *Eur J Haematol*. 2019 Jul;103(1):26-34.